Arinze Favour Anyiam

Mr. Arinze Favour Anyiam

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2023 in Scientific African
Verified
Journal Article
Open access
AOAugustine Anayochukwu Onyeaghala
Augustine Anayochukwu Onyeaghala
AAArinze Favour Anyiam
Arinze Favour Anyiam
DHDanladi Chiroma Husaini
Danladi Chiroma Husaini
EOEmmanuella Ogechi Onyeaghala
Emmanuella Ogechi Onyeaghala
EOEjeatuluchukwu Obi
Ejeatuluchukwu Obi
The advent of Corona virus Disease 2019 (COVID-19) distorted health systems of many countries. Efforts have been made to either develop new treatment solutions such as vaccines or repurpose previously adopted drugs. Challenges in accessing available treatment, inadequate, non-existent, or overstretched healthcare facilities, long COVID disease, cultural practices and beliefs about vaccination, vaccine hesitancy, availability, accessibility and perceived safety of herbal supplements seem to be major factors propelling individuals to use herbal supplements. Published reports advocating for clinical development of herbal supplements for COVID-19 and other emerging and re-emerging viral diseases are sparse. This paper aims to review the pathogenesis of COVID-19, use of herbal products during the pandemic and make case for clinical development of herbal supplements through the adoption of modern and acceptable technologies and research processes. This was a scoping review. Database searches of Google Scholar, PubMed and ResearchGate among others were performed using related keywords to identify relevant journals and lists of primary articles. Clinical trial databases:-Clinicaltrial.gov, Pan African Clinical Trial Registry (PACTR) and WHO international clinical trial registry (ICTRP) were reviewed to extract data. The use of herbal supplements during COVID-19 was not only peculiar to individuals living in Sub-Saharan Africa, but a global practice. Herbal supplements recommended to manage COVID-19 have not been validated using clinical trials. Available data showed that the number of herbal supplements undergoing clinical trial for COVID-19 indication in Africa was low. The availability of medicinal plants in Sub-Saharan Africa if well explored has great potentials to address various emerging and re-emerging viral diseases confronting the region. The economic potential of clinically validated herbal supplements are huge, and tapping into this opportunity created by preference of population to herbal supplement could increase export of herbal supplement and gross domestic product (GDP) of respective countries in Africa.

26 August 2024 in Biomed
Verified
Journal Article
Open access
PDF file
AMAdam Mustapha
Adam Mustapha
Ahmed Nouri AlsharksiAhmed Nouri Alsharksi
Ahmed Nouri Alsharksi
UEUkpai Eze
Ukpai Eze
RKRahma Samaila Kudla
Rahma Samaila Kudla
BUBoniface Nwofoke Ukwah
Boniface Nwofoke Ukwah
MIMusa Adamu Ibrahim
Musa Adamu Ibrahim
Klebsiella pneumoniae is an opportunistic Gram-negative bacterium in the Enterobacteriaceae family associated with a wide range of diseases, such as pneumonia, bloodstream infections, meningitis and urinary tract infections. Infections caused by drug-resistant strains of Klebsiella pneumoniae pose a significant threat to the effectiveness of conventional antibiotics. Hence, this has led to the need to explore alternative antimicrobial therapies, especially natural products derived from plant sources. This study assessed the phytochemical composition and antibacterial properties and performed a molecular docking analysis of Henna leaves (Lawsonia inermis L.) extracts on strains of Klebsiella pneumoniae. Crude ethanol and methanol extracts of L. inermis L. were prepared at different concentrations (25, 50, 75 and 100 mg/mL) and tested on extended spectrum beta-lactamases (ESBLs)-producing strains of Klebsiella pneumoniae. Phytocompounds were identified using gas chromatography–mass spectrometry (GC-MS) and further subjected to virtual ligands screening with DataWarrior (v05.02.01) and a molecular docking analysis using AutoDock4.2 (v4.2.6). The active compounds of L. inermis L. were determined by the docking analysis, including phytochemical, physicochemical, pharmacokinetics and docking score. The GC-MS analysis identified 27 phytoconstituents, including ethyl acetate, sclareol, 2-[1,2-dihydroxyethyl]-9-[β-d-ribofuranosyl] hypoxanthine, α-bisabolol and 2-Isopropyl-5-methylcyclohexyl 3-(1-(4-chlorophenyl)-3-oxobutyl)-coumarin-4-yl carbonate. The 27 compounds were then screened for their physicochemical and pharmacokinetic properties. The results revealed that the methanol extracts at 100 mg/mL showed significantly higher (p < 0.05) zones of inhibition (13.7 ± 1.2 mm), while the ethanol extracts at 50 mg/mL were significantly lower (6.3 ± 0.6 mm) compared to all the other treatments. The docking analysis revealed that out of the 27 compounds identified, only twelve (12) compounds have a drug-likeness activity. The 12 compounds were further subjected to docking analysis to determine the binding energies with the CTX-M protein of Klebsiella pneumoniae. Only one compound [CID_440869; (2-[1,2-dihydroxyethyl]-9-[β-d-ribofuranosyl] hypoxanthine)] had the best binding energy of −9.76 kcal/mol; hence, it can be considered a potentially suitable treatment for infections caused by ESBLs-producing strains of Klebsiella pneumoniae. This study has demonstrated that L. inermis L. extracts have antibacterial effects. Further research could explore the potential antimicrobial applications of L. inermis L. extracts to many bacterial strains.

22 August 2023 in Avicenna Journal of Medical Biochemistry
Verified
Journal Article
Open access
AAArinze Favour Anyiam
Arinze Favour Anyiam
EIEmmanuel ANYACHUKWU IRONDI
Emmanuel ANYACHUKWU IRONDI
EOEjeatuluchukwu Obi
Ejeatuluchukwu Obi
OAOnyinye Cecilia Arinze-Anyiam
Onyinye Cecilia Arinze-Anyiam
POPius Omoruyi Omosigho
Pius Omoruyi Omosigho
BOBlessing Ngozi Okezie
Blessing Ngozi Okezie
Background: It has been known for centuries that plants and plant-derived chemicals are useful in treating diseases, with Aloe vera being one of the biologically active plants. A significant role is played by the C-reactive protein (CRP) in many inflammatory conditions, while leukocytes play an integral role in the response of the immune system to infectious diseases. Objectives: This study explored the potential anti-inflammatory effects of Aloe vera methanolic extract on the total white blood cell (TWBC) count and CRP levels in Wistar rats received formalin. Methods: A total of 25 Wistar rats were divided into five groups (A to E), with group A serving as the control and the other groups receiving formalin to induce inflammation, followed by increasing doses of Aloe vera extract. The CRP level was measured using an enzyme-linked immunosorbent assay (ELISA) kit, and the TWBC count was determined using a Sysmex haematology autoanalyzer. Results: Research findings showed that 200 mg of Aloe vera methanolic extract effectively reduced the CRP level (0.056±0.0027) (P=0.04), while 600 mg of the extract significantly increased the TWBC count (13.920±4.757) (P=0.03). Conclusion: These findings suggest that Aloe vera extract may be an effective natural supplement for improving the immune system function and reducing inflammation in the body. However, further research is needed to fully understand the underlying mechanisms for these effects and to determine the optimal doses and potential side effects.


18 January 2025
Verified
Book Chapter
Closed access
PDF file
AAArinze Favour Anyiam
Arinze Favour Anyiam
OAOnyinye Cecilia Arinze-Anyiam
Onyinye Cecilia Arinze-Anyiam
EIEmmanuel ANYACHUKWU IRONDI
Emmanuel ANYACHUKWU IRONDI

11 April 2025 in Journal of Herbal Medicine
Verified
Journal Article
Closed access
AOA.A. Onyeaghala
A.A. Onyeaghala
AAArinze Favour Anyiam
Arinze Favour Anyiam
DHDanladi Chiroma Husaini
Danladi Chiroma Husaini
JCJ.H. Chiroma
J.H. Chiroma
OAO.C. Arinze-Anyiam
O.C. Arinze-Anyiam